Latest news with #BioAgeLabs
Business Insider
6 days ago
- Health
- Business Insider
BioAge Labs announces it will present new preclinical data on APJ agonism
BioAge Labs (BIOA) announced that it will present new preclinical data supporting apelin receptor, APJ, agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction. The data will be presented at the American Diabetes Association's 85th Scientific Sessions, held June 20-23, 2025, in Chicago, Illinois. In their two presentations, the company will present data that demonstrated that in preclinical models of diabetic obesity and HFpEF, APJ agonist treatment had potential as monotherapy that could be enhanced in combination with incretin therapies. Enhanced glycemic control in diabetic obesity – Dr. Rubin's oral presentation will show that in mouse models of diabetic obesity, APJ agonist monotherapy reduced HbA1c to levels comparable to lean controls and improved glucose tolerance by 25%. Cardioprotective effects in HFpEF – Dr. Yan's poster will show that in a mouse model of obesity-associated heart failure, APJ agonist monotherapy reduced cardiac hypertrophy and suppressed markers of cardiac injury. Combination of APJ agonism with an incretin provided enhanced cardioprotective benefits and greater weight loss compared to either treatment alone. Confident Investing Starts Here:
Yahoo
30-05-2025
- Business
- Yahoo
BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025
BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies for its groundbreaking oral NLRP3 inhibitor, BGE-102, targeting obesity. The company plans to submit an Investigational New Drug (IND) application by mid-2025, with first Phase 1 single ascending dose (SAD) data expected by year-end. A scientist in a lab coat analyzing samples from a petri dish, studying the effects of a potential drug candidate. BGE-102, an internally discovered compound, is distinguished by its novel binding site, high potency, and brain penetration. In preclinical obesity models, BGE-102 delivered dose-dependent weight loss comparable to leading GLP-1 agonist semaglutide, achieving up to 15% reduction as monotherapy and over 20% when combined with semaglutide. The drug also improved insulin sensitivity and demonstrated a robust safety margin in toxicology studies. BioAge Labs, Inc. (NASDAQ:BIOA)'s CEO, Kristen Fortney, Ph.D., highlighted BGE-102's potential as a once-daily oral therapy, either alone or with GLP-1 receptor agonists, by targeting the NLRP3 inflammasome, a key driver of inflammation and metabolic dysfunction in obesity. Pending IND clearance, BioAge Labs, Inc. (NASDAQ:BIOA) will launch Phase 1 trials, with a Phase 1b proof-of-concept study in obesity planned for late 2026. While we acknowledge the potential of BIOA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIOA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
27-05-2025
- Business
- Globe and Mail
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • Jefferies Global Healthcare Conference (New York, June 3–5, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. • Goldman Sachs 46th Annual Global Healthcare Conference (Miami, June 9–11, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Monday, June 9, 2025 at 3:20–3:55 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replays of the webcasts will be available in the investor section of the company's website at and will be archived for 30 days following the presentations. About BioAge Labs, Inc. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. BioAge's additional preclinical programs, which leverage insights from the Company's proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Yahoo
13-05-2025
- Business
- Yahoo
Longevity investment more than doubled to $8.5bn in 2024
Annual report reveals that global investment in longevity companies has grown 220% since 2023, despite fewer deals in total. LONDON, May 13, 2025 /PRNewswire/ -- Industry analysts at today published the 2024 Annual Longevity Investment Report – a full-year report on the state of investment in the longevity sector – with total financing reaching USD $8.49 billion across 331 deals. The report analyses the companies and investors behind technologies designed to extend the number of years we live in good health, breaking down the industry into 25 domains ranging from senotherapeutics and reproductive longevity to partial cellular reprogramming and immunity. It tracks investment data in public and private markets over the past 10 years, segmenting financing activity by location, domain and stage, addressing recent trends, and identifying the top segments and key players in longevity. This year's figures marked a strong rebound from a sharp downturn 2023, with the $3.74 billion raised in Q1 setting the tone for a steady upward trajectory through to Q4, which closed at $1.75 billion. Later stage VC continued to dominate, making up around a third of all funding. The US retained its position at the epicenter of longevity innovation, home to 57% of longevity companies and accounting for 84% of total deal volume. Investors heavily favored platform technologies, with longevity discovery platforms alone attracting more than $2 billion, reinforcing the field's strategic pivot toward foundational tools that support therapeutic discovery, and pipeline efficiency. "2024 was a year of renewed momentum for the longevity sector, reflecting growing investor confidence and a more selective, mature market approach," said Phil Newman, CEO of "Together, these trends reflect an industry moving beyond early-stage hype and into its execution phase." Investment highlights from the world of longevity biotech in 2024 included IPOs for BioAge Labs and Jupiter Neurosciences, as well as big funding rounds for senotherapeutics startup Rubedo Life Sciences and dog longevity biotech Loyal. But longevity isn't just about drug development, and investors also showed a keen interest in companies focused on consumer longevity applications, including a $200 million Series D round for smart ring leader ŌURA and a star-studded $53 million Series A for personalized prevention platform Function Health. "While investment activity is growing, it still falls short of the capital required to address the problem of mitigating the diseases of aging," added Newman. "Annual US healthcare expenditure hit $4.9tn in 2023, 85% of which went to chronic disease; every developed society is experiencing the same financial burden – the opportunity to develop and approve aging therapies remains untapped." Key report highlights: 2024 total financing: $8.49bn (up from $3.82bn in 2023). 2024 Total deal count: 325 deals (down from 331 deals in 2023). Notable quarters in 2024: $3.74bn in Q1. Top financing by deal type: Later stage VC (31% of total). Longevity companies by location: USA (57% of total). Deals by location: USA (84% of total). Top financing domain: Longevity discovery platforms ($2.65bn). The full report is free and available at: About is a UK-headquartered research, media and investment organisation exclusively focused on the longevity industry. bridges the gap between scientific advancements and investors, fostering collaboration among researchers, entrepreneurs, policymakers, and clinical practitioners to drive innovation and investment in healthspan extension and longevity. View original content: SOURCE Sign in to access your portfolio
Business Insider
07-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Immutep Ltd (OtherPRRUF)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioAge Labs, Inc. (BIOA – Research Report) and Immutep Ltd (PRRUF – Research Report). Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. BioAge Labs, Inc. (BIOA) In a report released today, Andy Hsieh from William Blair reiterated a Hold rating on BioAge Labs, Inc.. The company's shares closed last Tuesday at $3.95, close to its 52-week low of $3.80. According to Hsieh is a 4-star analyst with an average return of 6.0% and a 43.7% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Barinthus Biotherapeutics, and Corbus Pharmaceuticals. BioAge Labs, Inc. has an analyst consensus of Hold, with a price target consensus of $5.67. Immutep Ltd (PRRUF) In a report released today, Thomas Wakim from Bell Potter maintained a Buy rating on Immutep Ltd, with a price target of A$0.70. The company's shares closed last Monday at $0.22. According to Wakim is a 1-star analyst with an average return of -6.9% and a 40.0% success rate. Wakim covers the Healthcare sector, focusing on stocks such as Neuren Pharmaceuticals Limited, Clinuvel Pharmaceuticals, and Opthea. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immutep Ltd with a $0.98 average price target.
